Markets:

Overview

News

Currencies

International

Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

82.95 UNCHANGED

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

1 Reason LMAT is Risky and 1 Stock to Buy Instead

November 27, 2025

LeMaitre currently trades at $83.37 per share and has shown little upside over the past six months, posting a middling return of 2.9%. The stock also fell short of the S&P 500’s 15.6% gain during that...

Via StockStory

Topics Stocks Supply Chain

LeMaitre (LMAT) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

LeMaitre (LMAT) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

3 Healthcare Stocks We Steer Clear Of

November 24, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Via StockStory

Topics Stocks

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Via StockStory

Topics Economy

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

LeMaitre Vascular Inc (NASDAQ:LMAT) Stands Out as a Quality Investment Using the Caviar Cruise Screen ↗

November 14, 2025

LeMaitre Vascular (LMAT) is a high-quality medical device company with strong revenue & EBIT growth, a 32.83% ROIC, and a solid financial profile.

Via Chartmill

3 Russell 2000 Stocks Walking a Fine Line

November 13, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

5 Must-Read Analyst Questions From LeMaitre’s Q3 Earnings Call

November 13, 2025

LeMaitre’s third quarter results drew a negative market reaction as revenue trailed Wall Street expectations, despite solid year-over-year growth. Management cited strong performances from the Grafts...

Via StockStory

Topics Earnings

LMAT Q3 Deep Dive: Pricing and Margin Expansion Offset by Cautious Growth Outlook

November 07, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of...

Via StockStory

LeMaitre (NASDAQ:LMAT) Reports Sales Below Analyst Estimates In Q3 Earnings

November 06, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance...

Via StockStory

LeMaitre Earnings: What To Look For From LMAT

November 04, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Thursday after the bell. Here’s what investors should know.

Via StockStory

3 Cash-Producing Stocks We Think Twice About

October 31, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Where LeMaitre Vascular Stands With Analysts ↗

October 15, 2025

Via Benzinga

3 of Wall Street’s Favorite Stocks We Think Twice About

October 14, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: LeMaitre (NASDAQ:LMAT) Shines

October 06, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including LeMaitre (NASDAQ:LMAT) and its peers.

Via StockStory

Topics Artificial Intelligence Economy

1 High-Flying Stock with Solid Fundamentals and 2 We Ignore

October 06, 2025

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Via StockStory

Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement

September 30, 2025

New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a...

Via MarketMinute

Topics Government

Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge

September 30, 2025

Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...

Via MarketMinute

Topics Economy Government World Trade

AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know

September 30, 2025

A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.

Via StockStory

Topics Government

3 Reasons LMAT is Risky and 1 Stock to Buy Instead

September 30, 2025

Since March 2025, LeMaitre has been in a holding pattern, posting a small return of 1.8% while floating around $85.45. The stock also fell short of the S&P 500’s 18.6% gain during that period.

Via StockStory

Topics Stocks Supply Chain

Integra LifeSciences and LeMaitre Shares Are Falling, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Topics World Trade

1 Profitable Stock with Solid Fundamentals and 2 We Ignore

September 25, 2025

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

LeMaitre Vascular Inc. (NASDAQ:LMAT) Exemplifies Quality Investing Principles in Caviar Cruise Screen ↗

September 12, 2025

LeMaitre Vascular (LMAT) exemplifies quality investing with strong revenue growth, a 32.83% ROIC, and robust cash flow. A top pick from the Caviar Cruise screen for durable, high-quality stocks.

Via Chartmill

Astrana Health, Privia Health, Illumina, Waters Corporation, and LeMaitre Shares Plummet, What You Need To Know

September 10, 2025

A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.

Via StockStory

Topics Economy

Why LeMaitre (LMAT) Stock Is Down Today

September 03, 2025

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 2.2% in the afternoon session after the stock traded lower amid broader market weakness. U.S. stock markets began September trading...

Via StockStory

Topics Bonds Stocks World Trade

LMAT Q2 Deep Dive: International Expansion and Product Momentum Drive Upbeat Outlook

August 12, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 15% year on year to $64.23 million. Guidance for next...

Via StockStory

Why LeMaitre (LMAT) Stock Is Trading Up Today

August 06, 2025

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 9.5% in the afternoon session after the company reported better-than-expected second-quarter financial results and raised its...

Via StockStory

Topics ETFs Stocks World Trade

LeMaitre (LMAT) Q2 Revenue Jumps 15% ↗

August 06, 2025

Via The Motley Fool

LeMaitre (NASDAQ:LMAT) Exceeds Q2 Expectations, Full-Year Sales Guidance is Optimistic

August 05, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15% year on year to $64.23 million. Guidance for next quarter’s...

Via StockStory

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.